Rapport Therapeutics Inc. (RAPP)
Rapport Therapeutics Inc. (RAPP) Stock Price, Analysis & Data
| Bid | n/a |
| Market Cap | 2.35B |
| Revenue (ttm) | 20M |
| Net Income (ttm) | -137.16M |
| Beta | 0.97 |
| EPS (ttm) | -3.03 |
| PE Ratio (ttm) | n/a |
| Forward PE | -9.38 |
| P/B (ttm) | 5.56 |
| P/S (ttm) | 117.71 |
| Earnings Date | Nov 5, 2026 |
| Ask | n/a |
| Volume | 228,943 |
| Avg. Volume (20D) | 353,941 |
| Open | 49.58 |
| Previous Close | 49.01 |
| Day's Range | 48.68 - 49.90 |
| 52-Week Range | 13.90 - 49.90 |
| Analyst | Strong Buy |
| Price Target | 59 (20.24%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About RAPP
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment ...
Financial Performance
In 2025, Rapport Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -111.48M, an increase of 42.37%.
Financial StatementsAnalyst Forecast
According to 12 analyst ratings, the average rating for RAPP stock is "Strong Buy". The 12-month stock price forecast is 59, which is upside of 20.24% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
